Loading…
Akari Therapeutics, Plc is projected to rise to $8.28 by 2027, a +13% move from its current price of $7.36. AKTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $6.88 | $7.36 | $7.87 | +0.02% |
| Aug 6 | $6.70 | $7.36 | $8.10 | +0.04% |
| Aug 7 | $6.56 | $7.36 | $8.27 | +0.06% |
| Aug 8 | $6.44 | $7.37 | $8.42 | +0.07% |
| Aug 9 | $6.34 | $7.37 | $8.56 | +0.09% |
| Aug 10 | $6.25 | $7.37 | $8.68 | +0.11% |
| Aug 11 | $6.17 | $7.37 | $8.80 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.17 | $7.37 | $8.80 | +0.13% |
| Week 2 | $5.74 | $7.38 | $9.48 | +0.26% |
| Week 3 | $5.43 | $7.39 | $10.05 | +0.39% |
| Week 4 | $5.19 | $7.40 | $10.55 | +0.52% |
| Week 5 | $4.98 | $7.41 | $11.02 | +0.65% |
| Week 6 | $4.80 | $7.42 | $11.46 | +0.78% |
| Week 7 | $4.64 | $7.43 | $11.88 | +0.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Akari Therapeutics, Plc is an oncology company that develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. It also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. AKTX competes in the healthcare/biotech sector with a focus on oncology therapies.
Akari Therapeutics, Plc (AKTX) is a healthcare/biotech stock in oncology with a current price of $7.86 and a market cap of $13.76M. The stock is ranked 4992 by market capitalization.
The near-term price outlook shows a neutral stance in early forecasts, with 2026 forecasting an average price of $7.86, a min of $3.06 and a max of $12.03, and a 0% ROI. From 2027 through 2029 the average prices are $8.84, $8.77, and $8.18 respectively, with ROIs of 12.5%, 11.6%, and 4%, all described as Neutral sentiment.
Longer-term forecasts suggest a bearish turn in 2030 (avg $6.39, min $3.96, max $11.07, ROI -18.7) followed by a neutral stance in 2031 and 2032, then a bullish trajectory into 2033–2035 and strong upside by 2040 ($15.55 avg, $7.00 min, $34.09 max, ROI 97.8, Bullish) and 2050 ($19.38 avg, $8.72 min, $44.57 max, ROI 146.6, Bullish). These figures are the reported forecast outputs for AKTX.
A major floor 62.2% below — a decisive break under it would weaken the trend.
Support has flipped 6.8% overhead — reclaiming it would be bullish.
The nearest ceiling, 110.3% above — a clean break opens room to run.
A major ceiling 199.6% above — clearing it would confirm fresh momentum.
Key AKTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AKTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.20 | Sell | $8.28 | Sell |
| MA 10 | $8.88 | Sell | $8.98 | Sell |
| MA 20 | $10.89 | Sell | $9.96 | Sell |
| MA 50 | $12.16 | Sell | $10.46 | Sell |
| MA 100 | $8.85 | Sell | $10.83 | Sell |
| MA 200 | $12.39 | Sell | $16.11 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.60 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -100.33 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.37 | Sell |
| ROC (12) | -34.88 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.85 | Sell |
| Awesome (5,34) | -2.83 | Sell |
| Ultimate (7,14,28) | 8.31 | Buy |
| Momentum (10) | -3.15 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 7.77 | Sell |
| ADX (14) | 17.35 | Neutral |
| ATR (14) | 0.65 | Info |
The 30-day technical picture shows bearish sentiment with RSI(14) at 40. The stock is trading below the SMA50 of $12.16 and the SMA200 of $12.39, indicating a bearish slope in the near term.
Current price sits at $7.86 with near-term support at $7.86 and resistance at $15.48. The 30-day range is $5.05 to $12.23, highlighting notable volatility and a wide trading span. Annualized volatility is measured at 100%. These cues point to downside risk versus the resistance level in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.06 | $7.36 | $11.27 | 0% | Neutral | |
| $6.04 | $8.28 | $12.28 | +13% | Neutral | |
| $5.63 | $8.21 | $12.99 | +12% | Neutral | |
| $4.99 | $7.67 | $12.75 | +4% | Neutral | |
| $3.71 | $5.98 | $10.36 | -19% | Bearish | |
| $4.37 | $7.37 | $13.21 | 0% | Neutral | |
| $4.93 | $8.67 | $16.03 | +18% | Neutral | |
| $5.03 | $9.21 | $17.51 | +25% | Bullish | |
| $5.78 | $11.02 | $21.48 | +50% | Bullish | |
| $5.10 | $10.09 | $20.13 | +37% | Bullish | |
| $6.55 | $14.55 | $31.90 | +98% | Bullish | |
| $8.19 | $18.19 | $41.84 | +147% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.06 | $7.36 | $9.52 | +0.00% |
| September 2026 | $6.15 | $7.48 | $9.48 | +1.59% |
| October 2026 | $6.07 | $7.49 | $9.69 | +0.12% |
| November 2026 | $6.53 | $8.14 | $10.71 | +8.81% |
| December 2026 | $6.70 | $8.44 | $11.27 | +3.68% |
Click any year to see its month-by-month AKTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Akari Therapeutics, Plc's 2026 outlook centres on $7.36, within a $3.06 to $11.27 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, AKTX could reach as high as $12.28, with a base case around $8.28 and support toward $6.04 — roughly +13% from $7.36. Price action looks broadly range-bound.
Expect AKTX to range from $5.63 to $12.99 through 2028. The $8.21 average target implies a +12% move from current prices. That is -1% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The AKTX price prediction for 2029 points to an average of $7.67 (low $4.99, high $12.75) — a potential gain of +4% on today's $7.36. Price action looks broadly range-bound.
In 2030, AKTX is projected to trade between $3.71 and $10.36, averaging $5.98 — a potential decline of -19% from today's $7.36. That is -22% versus the projected 2029 average. Expect choppier, lower action through this leg of the cycle.
Akari Therapeutics, Plc's 2031 outlook centres on $7.37, within a $4.37 to $13.21 range. That is up +23% on the projected 2030 average. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2032, AKTX could reach as high as $16.03, with a base case around $8.67 and support toward $4.93 — roughly +18% from $7.36. A consolidation phase looks the most probable path here.
Expect AKTX to range from $5.03 to $17.51 through 2033. The $9.21 average target implies a +25% move from current prices. That is up +6% on the projected 2032 average. Momentum favours further upside here.
The AKTX price prediction for 2034 points to an average of $11.02 (low $5.78, high $21.48) — a potential gain of +50% on today's $7.36. Buyers look set to stay in control over this stretch.
In 2035, AKTX is projected to trade between $5.10 and $20.13, averaging $10.09 — a potential gain of +37% from today's $7.36. That is -8% versus the projected 2034 average. Momentum favours further upside here.
Akari Therapeutics, Plc's 2040 outlook centres on $14.55, within a $6.55 to $31.90 range. That is up +44% on the projected 2035 average. That marks a +98% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, AKTX could reach as high as $41.84, with a base case around $18.19 and support toward $8.19 — roughly +147% from $7.36. Momentum favours further upside here.
Investing $1,000 in AKTX today (≈ 135.869565 AKTX) could be worth
$2,471.67
+$1,471.67 (+147%) by 2050 · US Dollar
Based on the average projected AKTX price of $18.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AKTXwould be worth at today's price.
$1,000 invested in AKTX on Jul 31, 2025 (≈ 24.271844 AKTX) would be worth
$178.64
-$821.36 (-82.1%) today · 0.18× · US Dollar
Based on a AKTX entry price of $41.2 vs. today's $7.36.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.7 | $845.98 | -15.4% |
| 1 month ago | $10.25 | $718.05 | -28.2% |
| 3 months ago | $5.47 | $1,345.52 | +34.6% |
| 6 months ago | $9.48 | $776.37 | -22.4% |
| 1 year ago | $41.2 | $178.64 | -82.1% |
| All time (5.0y) ago | $1,352 | $5.44 | -99.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AKTX forecast.
Our base-case forecast reaches $15.00 around 2050.
Implied market cap at $15.00: $26.26M
The multi-year path assigns Neutral sentiment to 2026–2029, then moves to Bearish for 2030 before resuming Neutral in 2031–2032. A Bullish stance appears from 2033 onward, with substantial upside by 2040 and 2050.
In 2030 the average forecast price is $6.39 with a min of $3.96 and a max of $11.07, yielding a -18.7% ROI and a Bearish signal. By 2033 the average rises to $9.83 (min $5.36, max $18.68) with a 25% ROI and Bullish sentiment, followed by continued gains through 2034 ($11.78, ROI 49.9) and 2035 ($10.76, ROI 36.9). The 2040 forecast shows a strong rebound to an average of $15.55 with a 97.8% ROI and Bullish sentiment, and by 2050 the average is $19.38 with a 146.6% ROI and Bullish sentiment, supported by a broader price range ($8.72 min, $44.57 max).
These points illustrate a shift from a challenging near-term to meaningful long-term upside potential.
Tap a question to reveal the answer.
2030 avg $6.39; min $3.96; max $11.07; ROI -18.7; sentiment BEARISH.
Forecasts show Neutral sentiment for 2026–2029 with near-term averages around $7.86–$8.84 and ROIs of 0% to 12.5%. Longer term, 2033–2050 show a Bullish outlook with higher averages and positive ROIs, though outcomes are not guaranteed.
Yes. The 2040 forecast shows an average of $15.55 with a min of $7.00 and a max of $34.09, ROI 97.8, sentiment Bullish.
2033 avg $9.83; min $5.36; max $18.68; ROI 25; sentiment Bullish.
Current price is $7.86; 30-day range $5.05–$12.23; RSI(14) 40; SMA50 $12.16; SMA200 $12.39; support $7.86; resistance $15.48; sentiment Bearish.
Akari Therapeutics, Plc Community Discussion
0Share your Akari Therapeutics, Plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.